Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography
In an open clinical trial 13 depressives significantly improved under the reversible and selective type-A monoamine oxidase (MAO) inhibitor brofaromine. The inhibitory potency of deproteinated plasma on a crude MAO preparation from human placenta was measured as a parameter for plasma brofaromine. There were no significant differences in plasma MAO inhibitory potency between responders (improvement > 50%; n = 5) and non-responders. MAO inhibitory potency significantly (p < 0.05) increased parallel to the increase of the dosage from 50 mg b.i.d. to t.i.d. confirming the validity of this technique. The biologic assay, however, overestimated brofaromine by a factor of two in acute kinetic experiments with healthy volunteers as compared to a Chromatographic technique, although both methods significantly correlated (r = 0.928).
KeywordsMonoamine Oxidase Human Placenta Inhibitory Potency Dysthymic Disorder Endogenous Depression
Unable to display preview. Download preview PDF.
- Brotman AW, Falk WE, Gelenberg AJ (1987) Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1031–1040.Google Scholar
- Hengen N, Jedrychowski ME, Hoffmann E (1984) Pharmacokinetics of CGP 11 305A in man after acute and prolonged oral treatment. In: Tipton KF, Dostert P, Strolin-Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London, pp 185–191.Google Scholar
- Rudorfer MV, Potter WZ (1987) Pharmacokinetics of antidepressants. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1353–1363.Google Scholar
- Schiwy W, Heath WR, Delini-Stula A (1990) Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose finding trials in depressed patients. J Neural Transm [Suppl] 28:33–44.Google Scholar